19 May 2021
Government launches implementation plan to deliver world-leading genomic healthcare to patients, improving diagnosis, treatment and prevention
Diversity and reach of genomics set to expand through engagement and research programmes to better treat deadly diseases such as cancer
Patients across the UK will benefit from better healthcare, treatments and faster diagnosis as the government sets out how it will continue to deliver world-leading genomic healthcare.
Genomics is the study of genetic information and can help diagnose diseases earlier and more accurately, reduce some invasive procedures and enable tailored treatments. Building on the success of the 100,000 Genomes Project, our commitment is to sequence 1 million whole genomes – 500,000 genomes in the NHS and 500,000 in UK Biobank, which will transform healthcare in the UK and create jobs. In 2018 to 2019, genomics contributed £1.9 billion to our economy.
New coronavirus test with pop-up laboratories being piloted at four UK sites
PA
28 January 2021, 5:15 pm
A new Covid-19 test that is able to detect coronavirus in the saliva is being piloted for use in mobile laboratories across four sites in the UK.
The LamPORE Covid-19 test, developed by UK-based company Oxford Nanopore, has already started testing in Aberdeen, with plans to roll out in Telford, Brent and Newbury.
The technology will provide additional testing capacity where it is needed for large numbers of people, alongside existing PCR and lateral flow tests, the Department of Health and Social Care (DHSC) said.
A new Covid-19 test that is able to detect coronavirus in the saliva is being piloted for use Scotland. The LamPORE Covid-19 test, developed by UK-based company Oxford Nanopore, has already started testing in Aberdeen, with plans to roll out in Telford, Brent and Newbury in England The technology will provide additional testing capacity where it is needed for large numbers of people, alongside existing PCR and lateral flow tests, the Department of Health and Social Care (DHSC) said. Clinical evaluation conducted by NHS trusts and universities has shown the LamPORE test to have sensitivity (the ability of a test to correctly identify patients with a disease) of 99.57%, and specificity (the ability to correctly identify people without the disease) of 99.4%.
Clinical evaluation confirms high accuracy of highly mobile LamPORE test
Findings from large-scale technical and clinical evaluation of LamPORE COVID-19 test confirm high sensitivity and specificity.
From:
28 January 2021
Evaluation carried out by NHS trusts and universities finds test to be highly effective in detecting the virus in people with and without symptoms
LamPORE technology is highly mobile, with pop-up laboratories being piloted in Aberdeen, Telford, Brent and Newbury
A technical and clinical evaluation conducted by NHS trusts and universities has confirmed the LamPORE COVID-19 test, produced by Oxford Nanopore, to be accurate and sensitive enough to detect the virus in people with and without symptoms.
2 months old
This article is more than 2 months old
New test will probe genetics to predict reaction to chemotherapy and tailor treatment
The test previously available at a small number of hospitals, is now being rolled out across England. Photograph: Peter Byrne/PA
The test previously available at a small number of hospitals, is now being rolled out across England. Photograph: Peter Byrne/PA
PAMedia
Mon 28 Dec 2020 01.00 EST
Cancer patients in England will be offered a new test which aims to tailor treatments to their genetics and avoid toxic side-effects.
People with some cancers will receive a blood test which detects whether they are genetically prone to experiencing the more serious effects of chemotherapy drugs.